azilsartan vs olmesartan

PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.

Side-by-side comparison of azilsartan and olmesartan. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.

Drug Class
azilsartan Angiotensin II Receptor Blocker (ARB)
olmesartan Angiotensin II Receptor Blocker (ARB)
Type
azilsartan Prescription
olmesartan Prescription
Summary
azilsartan

No summary available.

olmesartan

No summary available.

What It Treats
azilsartan

Information not available.

olmesartan

Information not available.

How It Works
azilsartan

Information not available.

olmesartan

Information not available.

Common Side Effects
azilsartan
  • Dizziness
  • Fatigue
olmesartan
  • Nausea
  • High uric acid levels in the blood
  • Dizziness
  • Upper respiratory infection (like a cold)
FAERS Reports
azilsartan

No adverse event reports.

olmesartan

No adverse event reports.

Serious Warnings
azilsartan

No specific warnings noted.

olmesartan

No specific warnings noted.

Pregnancy
azilsartan

No pregnancy information available.

olmesartan

No pregnancy information available.

Also Compare, Nearby Drugs

How to Read This azilsartan vs olmesartan Comparison

azilsartan is classified in the Angiotensin II Receptor Blocker (ARB) drug class, while olmesartan sits within the Angiotensin II Receptor Blocker (ARB) class. Because both drugs share the same classification, they are often considered interchangeable in theory, but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.

Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, azilsartan has 0 submissions while olmesartan has 0. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.

A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for azilsartan or olmesartan.

Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.